High-dose therapy in lymphomas: A review of the current status of allogeneic and autologous stem cell transplantation in Hodgkin's disease and non-Hodgkin's lymphoma

Scott A. Mink, James Olen Armitage

Research output: Contribution to journalReview article

30 Citations (Scopus)

Abstract

Autologous stem cell transplantation has proven to be beneficial in selected patients with Hodgkin's disease (HD) and non-Hodgkin's lymphoma (NHL). In patients with HD, transplantation appears to increase event-free survival in patients who fail to enter complete remission with initial therapy. When a patient relapses after a complete remission, transplantation is probably the best option and particularly so if the remission lasted less than 1 year. Transplantation as part of primary therapy for very high-risk patients may be beneficial, but is not standard therapy at this time. For patients with diffuse large-cell NHL, transplantation can be considered standard therapy for relapsed patients if they have chemotherapy-sensitive disease. The use of transplantation for high-risk patients in complete remission is promising, but definite recommendations cannot be made at this time. For follicular lymphomas, selected patients seem to benefit and studies are ongoing. Finally, the use of allogeneic stem cell transplantation can be useful in a select group of younger patients.

Original languageEnglish (US)
Pages (from-to)247-256
Number of pages10
JournalOncologist
Volume6
Issue number3
DOIs
StatePublished - Jul 10 2001

Fingerprint

Stem Cell Transplantation
Hodgkin Disease
Non-Hodgkin's Lymphoma
Lymphoma
Transplantation
Therapeutics
Follicular Lymphoma
Disease-Free Survival
Recurrence
Drug Therapy

Keywords

  • Allogeneic transplantation
  • Autologous transplantation
  • Hematopoietic stem cell transplantation
  • High-dose therapy
  • Hodgkin's disease
  • Non-Hodgkin's lymphoma
  • Review

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

@article{bdc8dbb29b994fc887adaff07aace4ef,
title = "High-dose therapy in lymphomas: A review of the current status of allogeneic and autologous stem cell transplantation in Hodgkin's disease and non-Hodgkin's lymphoma",
abstract = "Autologous stem cell transplantation has proven to be beneficial in selected patients with Hodgkin's disease (HD) and non-Hodgkin's lymphoma (NHL). In patients with HD, transplantation appears to increase event-free survival in patients who fail to enter complete remission with initial therapy. When a patient relapses after a complete remission, transplantation is probably the best option and particularly so if the remission lasted less than 1 year. Transplantation as part of primary therapy for very high-risk patients may be beneficial, but is not standard therapy at this time. For patients with diffuse large-cell NHL, transplantation can be considered standard therapy for relapsed patients if they have chemotherapy-sensitive disease. The use of transplantation for high-risk patients in complete remission is promising, but definite recommendations cannot be made at this time. For follicular lymphomas, selected patients seem to benefit and studies are ongoing. Finally, the use of allogeneic stem cell transplantation can be useful in a select group of younger patients.",
keywords = "Allogeneic transplantation, Autologous transplantation, Hematopoietic stem cell transplantation, High-dose therapy, Hodgkin's disease, Non-Hodgkin's lymphoma, Review",
author = "Mink, {Scott A.} and Armitage, {James Olen}",
year = "2001",
month = "7",
day = "10",
doi = "10.1634/theoncologist.6-3-247",
language = "English (US)",
volume = "6",
pages = "247--256",
journal = "Oncologist",
issn = "1083-7159",
publisher = "AlphaMed Press",
number = "3",

}

TY - JOUR

T1 - High-dose therapy in lymphomas

T2 - A review of the current status of allogeneic and autologous stem cell transplantation in Hodgkin's disease and non-Hodgkin's lymphoma

AU - Mink, Scott A.

AU - Armitage, James Olen

PY - 2001/7/10

Y1 - 2001/7/10

N2 - Autologous stem cell transplantation has proven to be beneficial in selected patients with Hodgkin's disease (HD) and non-Hodgkin's lymphoma (NHL). In patients with HD, transplantation appears to increase event-free survival in patients who fail to enter complete remission with initial therapy. When a patient relapses after a complete remission, transplantation is probably the best option and particularly so if the remission lasted less than 1 year. Transplantation as part of primary therapy for very high-risk patients may be beneficial, but is not standard therapy at this time. For patients with diffuse large-cell NHL, transplantation can be considered standard therapy for relapsed patients if they have chemotherapy-sensitive disease. The use of transplantation for high-risk patients in complete remission is promising, but definite recommendations cannot be made at this time. For follicular lymphomas, selected patients seem to benefit and studies are ongoing. Finally, the use of allogeneic stem cell transplantation can be useful in a select group of younger patients.

AB - Autologous stem cell transplantation has proven to be beneficial in selected patients with Hodgkin's disease (HD) and non-Hodgkin's lymphoma (NHL). In patients with HD, transplantation appears to increase event-free survival in patients who fail to enter complete remission with initial therapy. When a patient relapses after a complete remission, transplantation is probably the best option and particularly so if the remission lasted less than 1 year. Transplantation as part of primary therapy for very high-risk patients may be beneficial, but is not standard therapy at this time. For patients with diffuse large-cell NHL, transplantation can be considered standard therapy for relapsed patients if they have chemotherapy-sensitive disease. The use of transplantation for high-risk patients in complete remission is promising, but definite recommendations cannot be made at this time. For follicular lymphomas, selected patients seem to benefit and studies are ongoing. Finally, the use of allogeneic stem cell transplantation can be useful in a select group of younger patients.

KW - Allogeneic transplantation

KW - Autologous transplantation

KW - Hematopoietic stem cell transplantation

KW - High-dose therapy

KW - Hodgkin's disease

KW - Non-Hodgkin's lymphoma

KW - Review

UR - http://www.scopus.com/inward/record.url?scp=0034958373&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034958373&partnerID=8YFLogxK

U2 - 10.1634/theoncologist.6-3-247

DO - 10.1634/theoncologist.6-3-247

M3 - Review article

C2 - 11423671

AN - SCOPUS:0034958373

VL - 6

SP - 247

EP - 256

JO - Oncologist

JF - Oncologist

SN - 1083-7159

IS - 3

ER -